Skip to main content

Table 3 Course of symptoms during observational period; patients with symptoms at initial visit (efficacy population)

From: Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)

Symptom

Total

Relieved

Improved

Unchanged

Worsened

Missing

n (%)a

n (%)b

n (%)b

n (%)b

n (%)b

n (%)b

Fever

1768 (69.7)

1713 (96.9)

5 (0.3)

15 (0.8)

0 (0.0)

35 (2.0)

Cough

2512 (99.1)

1666 (66.3)

495 (19.7)

320 (12.7)

1 (< 0.1)

30 (1.2)

Dyspnea

2298 (90.6)

1615 (70.3)

399 (17.4)

245 (10.7)

1 (< 0.1)

38 (1.7)

Sputum volume

2471 (97.4)

1364 (55.2)

846 (34.2)

226 (9.1)

8 (0.3)

27 (1.1)

Sputum character

2284 (90.1)

1350 (59.1)

446 (19.5)

73 (3.2)

1 (< 0.1)

414 (18.1)

Chest discomfort

2116 (83.4)

1822 (86.1)

103 (4.9)

152 (7.2)

1 (< 0.1)

38 (1.8)

Fatigue

1984 (78.2)

1573 (79.3)

180 (9.1)

186 (9.4)

0 (0.0)

45 (2.3)

Sleep disturbances

1672 (65.9)

1521 (91.0)

45 (2.7)

78 (4.7)

1 (0.1)

27 (1.6)

  1. aProportion of the efficacy population (n = 2536); bproportion of the patients who had symptoms at initial visit.